(0)
Argenta Limited ( Argenta ), the only global contract research organization (CRO) and contract development and manufacturing organization (CDMO) specializing in animal health, and NovaQuest Capital Management ( NovaQuest ) announced today a $30 million product financing agreement for the development of several innovative veterinary pharmaceuticals.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210520005132/en/
The collaboration leverages NovaQuest s capital and expertise, and Argenta s knowledge and know-how in research and development activities that advance animal health. The capital investment from NovaQuest accelerates Argenta s strategy of providing innovative solutions and Molecule to Market services through global partnerships. We are delighted by the collaboration with NovaQuest and we look forward to strengthening our partnership through additional programs in the future, said Ben Russell, CEO of Arge
Argenta Enters $30 Million Product Financing Agreement with NovaQuest to Accelerate New Veterinary Product Development
on May 20 2021 8:30 PM
RALEIGH, N.C. & AUCKLAND, New Zealand (BUSINESS WIRE) Argenta Limited (“Argenta”), the only global contract research organization (CRO) and contract development and manufacturing organization (CDMO) specializing in animal health, and NovaQuest Capital Management (“NovaQuest”) announced today a $30 million product financing agreement for the development of several innovative veterinary pharmaceuticals.
The collaboration leverages NovaQuest’s capital and expertise, and Argenta’s knowledge and know-how in research and development activities that advance animal health.
“The capital investment from NovaQuest accelerates Argenta’s strategy of providing innovative solutions and Molecule to Market services through global partnerships. We are delighted by the collaboration with NovaQuest and we look forward to strengthening our partn
Published: May 03, 2021
Acquires worldwide rights to RVT-801, a novel enzyme replacement therapy for treatment of Farber disease
NovaQuest investment to fund product and clinical development
Protocol for potential single registration study reviewed with FDA and EMA
Program has been granted rare pediatric disease status, fast track and orphan designations, and is eligible for a priority review voucher once approved
RESEARCH TRIANGLE PARK, N.C. & BASEL, Switzerland (BUSINESS WIRE)
Aceragen, Inc., a biopharmaceutical company focused on advancing transformational therapeutics for rare and ultra-rare diseases, today announced the acquisition of Enzyvant’s RVT-801 (now ACG-801), an investigational enzyme replacement therapy (ERT) for acid ceramidase deficiency presenting as Farber disease, a lysosomal storage disease with a unique, severe inflammatory phenotype for which no disease-specific therapy exists. Enzyvant will receive an upfront payment and development and sales-ba
Leeds Equity Partners and OptionMetrics Partner to Expand Options and Futures Data Solutions
Private equity firm dedicated to creating long-term value for companies in Knowledge Industries makes significant investment in leading options and futures data and analytics provider
News provided by
Share this article
Share this article
NEW YORK, April 30, 2021 /PRNewswire/ Leeds Equity Partners ( Leeds Equity ), the New York-based private equity firm, and OptionMetrics, the options and futures database and analytics provider for institutional investors and academic researchers worldwide, announced today that Leeds Equity is investing in OptionMetrics. OptionMetrics represents the first investment platform for Leeds Equity Partners VII, L.P. Terms of the transaction were not disclosed.
Cerevel Therapeutics Announces Strategic $125 Million Non-Dilutive Financing Transaction for Tavapadon forextv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forextv.com Daily Mail and Mail on Sunday newspapers.